Study S000053

Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE): a Randomized, Double-Blind, Placebo-Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07859150
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 104
Start: 2026-10
Primary completion: 2029-04
Lead sponsor: General Committee of Teaching Hospitals and Institutes, Egypt
Conditions: Morbid Obesity
Interventions: DRUG:Semaglutide weekly injection; DRUG:Placabo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Mean percentage change in body weight from randomization [week 0 to week 68]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.